PURPOSE:alpha-lipoic acid is an essential cofactor for mitochondrial respiratory enzymes that improves mitochondrial function. We previously reported that alpha-lipoic acid markedly reduced body weight gain in rodents. The purpose of this study was to determine whether alpha-lipoic acid reduces body weight in obese human subjects. METHODS: in this randomized, double-blind, placebo-controlled, 20-week trial, 360 obese individuals (body mass index [BMI] ≥ 30 kg/m(2) or BMI 27-30 kg/m(2) plus hypertension, diabetes mellitus, or hypercholesterolemia) were randomized to alpha-lipoic acid 1200 or 1800 mg/d or placebo. The primary end point was body weight change from baseline to end point. RESULTS: the 1800 mg alpha-lipoic acid group lost significantly more weight than the placebo group (2.1%; 95% confidence interval, 1.4-2.8; P<.05). Urticaria and itching sensation were the most common adverse events in the alpha-lipoic acid groups, but these were generally mild and transient. CONCLUSION:alpha-lipoic acid 1800 mg/d led to a modest weight loss in obese subjects. Alpha-lipoic acid may be considered as adjunctive therapy for obesity. 2011 Elsevier Inc. All rights reserved.
RCT Entities:
PURPOSE:alpha-lipoic acid is an essential cofactor for mitochondrial respiratory enzymes that improves mitochondrial function. We previously reported that alpha-lipoic acid markedly reduced body weight gain in rodents. The purpose of this study was to determine whether alpha-lipoic acid reduces body weight in obesehuman subjects. METHODS: in this randomized, double-blind, placebo-controlled, 20-week trial, 360 obese individuals (body mass index [BMI] ≥ 30 kg/m(2) or BMI 27-30 kg/m(2) plus hypertension, diabetes mellitus, or hypercholesterolemia) were randomized to alpha-lipoic acid 1200 or 1800 mg/d or placebo. The primary end point was body weight change from baseline to end point. RESULTS: the 1800 mg alpha-lipoic acid group lost significantly more weight than the placebo group (2.1%; 95% confidence interval, 1.4-2.8; P<.05). Urticaria and itching sensation were the most common adverse events in the alpha-lipoic acid groups, but these were generally mild and transient. CONCLUSION:alpha-lipoic acid 1800 mg/d led to a modest weight loss in obese subjects. Alpha-lipoic acid may be considered as adjunctive therapy for obesity. 2011 Elsevier Inc. All rights reserved.
Authors: A E Huerta; P L Prieto-Hontoria; M Fernández-Galilea; N Sáinz; M Cuervo; J A Martínez; M J Moreno-Aliaga Journal: J Physiol Biochem Date: 2015-03-28 Impact factor: 4.158
Authors: V Mohammadi; M Khalili; S Eghtesadi; S Dehghani; S Jazayeri; S K Aghababaee; H Sabour; H Saberi; M Eghtesadi; M R Gohari Journal: Spinal Cord Date: 2015-03-10 Impact factor: 2.772
Authors: Sandra L Rebholz; Thomas Jones; Katie T Burke; Anja Jaeschke; Patrick Tso; David A D'Alessio; Laura A Woollett Journal: Am J Physiol Endocrinol Metab Date: 2011-11-29 Impact factor: 4.310
Authors: Nouf M Al-Rasheed; Nawal M Al-Rasheed; Hala A Attia; Iman H Hasan; Maha Al-Amin; Hanaa Al-Ajmi; Raeesa A Mohamad Journal: J Physiol Biochem Date: 2013-04-18 Impact factor: 4.158
Authors: Gerd Bobe; Alexander J Michels; Wei-Jian Zhang; Jonathan Q Purnell; Clive Woffendin; Cliff Pereira; Joseph A Vita; Nicholas O Thomas; Maret G Traber; Balz Frei; Tory M Hagen Journal: J Nutr Date: 2020-09-01 Impact factor: 4.798